Table 1.
Baseline characteristics of identified patients with EC initiating an anticancer treatment following a platinum-based therapy
| Identified EC patient starting a post-platinum-based therapy | |
|---|---|
| N | 201 |
| Mean/median follow-up time in days (SD│range) | 613.6/335 (675.3│8–3,257) |
| Mean/median time from first observable EC treatment until index date in days (SD│range) | 396.5/283 (367.1│91–3,085) |
| Main characteristics assessed in the fixed 12-month pre-index period | |
| Mean/median age in years (SD│range) | 68.9/71.0 (9.2│35–86) |
| Mean CCI (SD│range) | 9.3 (2.7│2–18) |
| N (%) patients documented with another primary malignant neoplasm | 177 (88.1) |
| Location | |
| Other female genital organs | 134 (66.7) |
| Mesothelial and soft tissue | 35 (17.4) |
| Breast | 32 (15.9) |
| Digestive organs | 24 (11.9) |
| Respiratory and intrathoracic organs | 19 (9.5) |
| Other specified sites (N < 10 patients) | 23 (9.5) |
| N (%) patients documented with a secondary malignant neoplasm | 170 (84.2) |
| Location | |
| Respiratory or digestive organs nodes | 138 (68.7) |
| Lymph | 82 (40.8) |
| Other or unspecified sites | 77 (38.3) |
| N (%) patients with MSI-H/dMMR test | 12 (6.0) |
CCI Charlson Comorbidity Index, dMMR defect in mismatch repair gene, EC endometrial cancer, MSI-H high levels of microsatellite instability, SD standard deviation